Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBIT (2016 - 2025)

Abeona Therapeutics has reported EBIT over the past 15 years, most recently at -$22.9 million for Q4 2025.

  • Quarterly results put EBIT at -$22.9 million for Q4 2025, down 37.42% from a year ago — trailing twelve months through Dec 2025 was -$89.4 million (down 39.3% YoY), and the annual figure for FY2025 was -$89.4 million, down 39.3%.
  • EBIT for Q4 2025 was -$22.9 million at Abeona Therapeutics, up from -$24.0 million in the prior quarter.
  • Over the last five years, EBIT for ABEO hit a ceiling of -$8.0 million in Q2 2022 and a floor of -$46.7 million in Q4 2021.
  • Median EBIT over the past 5 years was -$14.7 million (2021), compared with a mean of -$17.1 million.
  • Biggest five-year swings in EBIT: plummeted 222.18% in 2021 and later soared 72.27% in 2022.
  • Abeona Therapeutics' EBIT stood at -$46.7 million in 2021, then soared by 72.27% to -$12.9 million in 2022, then fell by 2.11% to -$13.2 million in 2023, then fell by 26.22% to -$16.7 million in 2024, then crashed by 37.42% to -$22.9 million in 2025.
  • The last three reported values for EBIT were -$22.9 million (Q4 2025), -$24.0 million (Q3 2025), and -$22.8 million (Q2 2025) per Business Quant data.